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Background: We sought to improve prostate cancer (PC) detection through developing a prostate biopsy clinical
decision rule (PBCDR), based on an elevated PSA and laboratory biomarkers. This decision rule could be used after
initial PC screening, providing the patient and clinician information to consider prior to biopsy.
Methods: This case–control study evaluated men from the Tampa, Florida, James A. Haley (JH) Veteran’s
Administration (VA) (N = 1,378), from January 1, 1998, through April 15, 2005. To assess the PBCDR we did all of the
following: 1) Identified biomarkers that are related to PC and have the capability of improving the efficiency of PC
screening; 2) Developed statistical models to determine which can best predict the probability of PC; 3) Compared
each potential model to PSA alone using Receiver Operator Characteristic (ROC) curves, to evaluate for improved
overall effectiveness in PC detection and reduction in (negative) biopsies; and 4) Evaluated dose–response
relationships between specified lab biomarkers (surrogates for extra-prostatic disease development) and PC
progression.
Results: The following biomarkers were related to PC: hemoglobin (HGB) (OR = 1.42 95% CI 1.27, 1.59); red blood
cell (RBC) count (OR = 2.52 95% CI 1.67, 3.78); PSA (OR = 1.04 95% CI 1.03, 1.05); and, creatinine (OR = 1.55 95% CI
1.12, 2.15). Comparing all PC stages versus non-cancerous conditions, the ROC curve area under the curve (AUC)
enlarged (increasing the probability of correctly classifying PC): PSA (alone) 0.59 (95% CI 0.55, 0.61); PBCDR model
0.68 (95% CI 0.65, 0.71), and the positive predictive value (PPV) increased: PSA 44.7%; PBCDR model 61.8%.
Comparing PC (stages II, III, IV) vs. other, the ROC AUC increased: PSA (alone) 0.63 (95% CI 0.58, 0.66); PBCDR model
0.72 (95% CI 0.68, 0.75), and the PPV increased: 20.6% (PSA); PBCDR model 55.3%.
Conclusions: These results suggest evaluating certain common biomarkers in conjunction with PSA may improve
PC prediction prior to biopsy. Moreover, these biomarkers may be more helpful in detecting clinically relevant PC.
Follow-up studies should begin with replicating the study on different U.S. VA patients involving multiple practices.Background
The number of men who undergo prostate biopsies to rule
out prostate cancer (PC) increases annually (estimated at
over one million per year) [1]. This is in large part a result
of elevated serum prostate specific antigen (PSA) values
identified during routine PC screening [2,3]. Debate over
the appropriateness of PC screening continues [1-7]. In
addition, there is considerable controversy over the course
one should take upon detecting PSA elevations [2-5].* Correspondence: owen.hill@us.army.mil
1Injury Epidemiology Research Section, Military Performance Division, United
States Army Institute of Environmental Medicine, Natick, MA, USA
Full list of author information is available at the end of the article
© 2013 Hill et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orMoreover, it is inconclusive whether early PC detection
results in lower morbidity and mortality for the men iden-
tified [3-6].
PC screening has been fraught with controversy and the
overtreatment of low-risk PC is considered a major public
health problem [8,9]. The U.S. Preventive Services Task
Force (USPSTF), National Cancer Institute (NCI), World
Health Organization (WHO), and other international
agencies do not recommend PC screening [7]. Conversely,
the American Cancer Society (ACS), American College of
Radiology (ACR), and the American Urological Asso-
ciation (AUA) recommend screening men above the age
of 50 with a routine serum PSA and digital rectal exam. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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it is a valuable early detection tool as it can identify PC in
asymptomatic men prior to clinical presentation. In
theory, earlier identified PC should be at a less advanced
stage, which implies a more treatable state. This is contro-
versial, as PC is heterogeneous, in some cases indolent
(never becoming clinically evident), while in other cases
PC can be aggressive, rapidly advancing from a pre-
clinical state to distant metastases [8].
An easy to implement screening tool that detects
‘aggressive’ PC is needed. The primary goal of PC
screening is to detect cancer before it is too advanced
for treatment, and to bypass the tumors that are not
destined to shorten a man’s life [9]. With that stated,
delineation between different types of PC is difficult, but
of paramount importance. PSA research over the last
two decades has improved our ability to identify PC
[2,3,8,10]. However; this has resulted in needless biopsies
and treatments and is a reason for the protracted debate
over the PSA utility as a PC screening tool [3].
Despite a wealth of published literature that has eva-
luated PSA and argued against its use, it remains a
mainstay for patients and clinicians. Prior attempts at
improving PC screening have focused on replacing PSA
with a new test. Tools such as PSA velocity, PSA density,
Free/Total PSA ratio, and PCA3 testing have all shown
promise for improving PC screening, but difficult imple-
mentation and a lack of universal acceptance among
clinicians have hindered incorporation into daily clinical
practice [2,3,5]. Clearly, PC screening is in need of
improvement. Therefore, the purpose of this investiga-
tion was to improve the efficiency of PC detection
through the development of a novel clinical decision
rule. We investigated and propose the prostate biopsy
clinical decision rule (PBCDR) that implements both ele-
vated PSA and readily available laboratory biomarkers. If
accurate, the PBCDR could be used as an advanced
screening tool after PSA as it provides additional clinic-
ally significant information to assist the clinician and pa-
tient in reaching a decision regarding the urgency of a
prostate biopsy.
To develop and validate this advanced screening tool
we did all of the following: (1) Identified biomarkers that
are related to PC and have the capability of improving
the efficiency of PC screening; (2) Developed statistical
models to determine which can best predict the prob-
ability of PC; (3) Compared each potential model to the
current screening tool (PSA only) using ROC curves, to
evaluate for improved overall effectiveness in PC detec-
tion and reduction in (negative) biopsies; (4) Evaluated
dose–response relationships between specified lab bio-
markers (surrogates for extra-prostatic disease develop-
ment) and PC progression. If present, the degree of
change between the reference ‘normal’ value and theobserved lab value could provide valuable insight for dif-
ferentiating between indolent and clinically relevant PC.
Methods
Population, inclusion/exclusion criteria, and data sources
This study was a case–control analysis, evaluating 1,378
prior military servicemen (40–90 years of age), from the
James A. Haley Veteran’s Administration (VA) hospital
from January 1, 1998 through April 15, 2005 who had
undergone prostate biopsy. Only patients with a PSA
value of 4 ng/dL (or higher), with laboratory data
obtained at the time of the PSA sample, and an initial
diagnosis of PC, prostatic interstitial neoplasm (PIN),
benign prostatic hypertrophy (BPH), or prostatitis were
included in the analysis. Patients with history of prior
genital urinary malignancy, and those with inadequate
biopsy specimens were excluded from analysis. Subjects
meeting inclusion criteria were classified into one of four
‘histology’ groups. The cases consist of biopsy-confirmed
PC. The non-PC cases were classified into three groups:
(1) PIN, (2) BPH, or (3) prostatitis. Biopsies with isolated
atypical small acinar proliferation were included in the
PIN group. This study was approved by the Institutional
Review Board at the University of South Florida and
James A. Haley VA hospital.
Case identification/data collection methods
A case of PC is defined by prostate tissue that demon-
strates cells of adenocarcinoma on histologic evaluation
[11]. With that, identification of study subjects was
accomplished through searching the Anatomic Pat-
hology portion of VisTa (Systematized Nomenclature of
Medicine (SNOMED) finalized accession logs) to find all
cases coded as 'prostate disease' (SNOMED codes:
77220, 77103, 77102, 77101, 77110, 77105, 77350,
77230, 77210, 77300, 77200, 77240, 77104, 77100,
77000, 77900, 77250). SNOMED is a classification
system of the College of American Pathologists, and is
the standard tool used by pathologists to create, share,
and retrieve pathology information. The patient’s identi-
fication number, date of the specimen, diagnosis text
code, and accompanying narrative text description were
captured through this VISTA search. The collection of
both the diagnosis text code and accompanying text de-
scription was performed intentionally as a way to valid-
ate the histologic diagnosis. For instance, if the diagnosis
code was ‘adenocarcinoma of the prostate’ (SNOMED
code 77220); the corresponding narrative text descrip-
tion would provide the same diagnosis. The goal of this
initial search was to capture all prostate related cases;
hence the large number of SNOMED codes used.
The James Haley VA electronic medical records (EMR)
were then accessed for all of the potential PC cases to va-
lidate the diagnosis. This was accomplished by confirming
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(ICD–9) PC codes and capturing basic demographic,
laboratory biomarkers, and any previous pathology results.
Data reduction strategies were employed which ultim-
ately left 1,378 participants available (from 2,575 poten-
tial subjects) for statistical analysis. Over 500 prostate
biopsies (541) did not meet inclusion criteria because
they were performed on men who did not have a PSA
test value of 4.0 ng/dL or greater. Typical situations that
would result in this scenario include biopsies secondary
to suspicious DRE or Transrectal ultrasound (TRUS), or
other reasons (e.g. positive family history). There were
321 biopsies identified as “repeat biopsies”, which were
then dropped from the study. Next, biopsies performed
as a result of other genital urinary malignancies
(i.e. bladder, renal, ureter, and penile cancer) (N=260)
were excluded. It is important to note that the specific
prompting for all prostate biopsies was confirmed
through a detailed record review of each prostate biopsy
report within the VISTA system. These notes were in
narrative form and were validated by confirming the
ICD-9 code for that event. Lastly, participants without a
full complement of laboratory biomarkers were excluded
from the study (N=75). Thus our final analysis was
based on 1,378 patients.
Outcomes - PC classification
PC classification was based on Stage and Gleason sum
for each patient with histologic confirmation of PC.
The Stages were categorized as follows: Stage I for
non-palpable, prostate contained cancer (analogous to T1
non-palpable PC); Stage II for palpable prostate contained
cancer (analogous to T2 palpable PC); Stage III for locally
spread PC (analogous to T3/T4 PC); and Stage IV for
metastatic PC (analogous to M1 PC). To determine the
Gleason sum, the two most prominent areas of PC activity
(as identified by the evaluating pathologist on histologic
examination) were identified. Each prominent area was
given a score of 1–5, with 1 being well differentiated,
and 5 being poorly differentiated (implying a more aggres-
sive appearance). The two scores are added together, and
this number was the recorded Gleason sum for all subse-
quent analyses.
Statistical analysis
Univariate, bivariate, logistic regression, linear regression,
and receiver operator characteristic (ROC) curves were
utilized. Data were analyzed utilizing SAS statistical soft-
ware. Descriptive analysis allowed for careful review of
data frequencies, measures of central tendency, and distri-
bution shapes. Bivariate analysis tested all identified bio-
markers to determine the statistical significance and
degree of correlation between these independent variables
and PC. Multivariate logistic regression was utilized toevaluate which statistical model can best predict the prob-
ability of PC.
We first defined a “Case” as any stage of PC and
a “Control” as any non-cancerous prostate condition
(PIN, BPH, and prostatitis). In a secondary analysis, we
redefined a “Case” as PC stages (II, III, IV) and “Control”
as stage I PC, or any non-cancerous prostate condition.
Our reasoning was that as Stage 1 cancer is localized, it
may be unlikely to progress to advanced disease.
A complete model (including age, ethnicity, biomarkers,
and any interaction terms) was established initially. Exclu-
sion of each covariate was performed, looking for a change
in the overall – 2 Log Likelihood Ratio. A potential cova-
riate was permanently removed from the model develop-
ment process if there was no effect on the overall – 2 Log
Likelihood value. This lack of change indicates the variable
is not contributing to the prediction of the outcome, and
conversely, if there was a change of statistical significance,
the variable was included in the final model. To test for
differences between the full model and the final model,
evaluation of the likelihood ratio p-value was performed,
in which a value greater than 0.05 indicated a satisfactory
fit of the smaller model. Regression diagnostic techniques
were employed to increase the reliability of the data.
ROC curves were used to address which statistical
models could best predict the probability of PC and if a
dose–response relationship existed between specified lab
biomarkers and PC progression. ROC curves are graphical
tools, which plot the sensitivity vs. 1- the specificity for a
binary classification system (as a function of changes in
the cut-off value threshold). This analysis technique was
used to judge the validity of proposed model. Mean and
median values of all significant biomarkers were deter-
mined for each PC stage subset to determine if a gradient
exists between advancing PC severity and laboratory
biomarkers.
Results
Table 1 outlines the demographics of the study partici-
pants. The mean age of the subjects was 68 years
(SD=8.5). Most of the men had either prostatitis, BPH,
or stage I PC (79.4%). Stage II, III and IV PC accounted
for 20.6% of all diagnoses. The study population was
largely Caucasian (study total=70.75%, PC=69.4%,
PIN=71.73%, BPH=74.82%, prostatitis=69.29%). Age at
diagnosis (PC stage I group=68.37, PC stage II
group=69.73, PC stage III group=67.73, stage IV group
67.88, PIN group=67.75, BPH group=67.83, prostatitis
group=68.17) was comparable across all diagnosis
groups.
Table 2 outlines the mean value and standard devi-
ation of all continuous laboratory biomarkers by the
prostate biopsy results. The mean values of albumin,
hemoglobin (HGB), RBC count, creatinine, and folate all
Table 1 Demographics of study particpants by prostate biopsy results
Prostatitis BPH PIN PC stage I PC stage II PC stage III PC stage IV
N=342 N=282 N=138 N=332 N=220 N=48 N=16
Ethnicity*
Caucasian 237(69%) 211(75%) 99 (72%) 238 (72%) 149 (68%) 31(65%) 10 (63%)
Black 18 (5%) 19 (7%) 13 (9%) 34 (10%) 22 (10%) 7 (15%) 4 (25%)
Hispanic 22 (6%) 14 (5%) 7 (5%) 15 (5%) 11 (5%) 1 (2%) 1 (6%)
Other 65 (20%) 38 (14%) 19 (14%) 45 (13%) 38 (17%) 9 (18%) 1 (6%)
Mean Age** 68.17 67.83 67.75 68.37 69.73 67.73 67.88
SD Age 8.54 8.19 8.49 8.99 9.36 9.39 10.6
* P-value < 0.05.
** Not statistically significant.
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mean value of PSA increased as PC stage increased. No
trends were observed for mean values of mean corpus-
cular volume (MCV), BUN, platelet count, WBC, LDH,
and bilirubin. Trend significance tests revealed that as
the prostate biopsy result increased from prostatitis to
stage IV PC, the mean value of HGB, creatinine, PSA,
and BUN varied from reference normal (p < 0.05). No
trends were observed for the lab biomarkers RBC, MCV,
albumin, WBC, bilirubin, and platelet count.
Crude Odds Ratios (with 95% CI) for the association
of each laboratory biomarker with PC are presented in
two ways:
Primary analysis: all PC stages vs. non-cancerous
prostate conditions
Secondary analysis: PC (stages II, III, IV) vs. (PC stage
I, PIN, BPH, and prostatitis)
Primary analysis
In this analysis, Hemoglobin, PSA, and serum BUN were
related significantly to PC positive cases (when compared
to non-cancerous prostate conditions) (Table 3).
Secondary analysis
When the stage I PC subjects were placed in the compari-
son group (leaving stage II, III, and IV PC subjects as the
‘cases’), hemoglobin, age, PSA, hematuria, and RBC count
demonstrated statistically significant relationships with the
PC positive cases (when compared to the comparison
group: stage I PC, PIN, BPH, and prostatitis) (Table 4).
Table 5 summarizes laboratory biomarkers, which dem-
onstrate a statistically significant relationship with PC.
Table 6 outlines the PPV of PSA (> 4 ng/dL) alone for
PC detection. This PPV was evaluated as method 1 and
2 (described above).
The positive predictive value was decreased significantly
when stage I PC was not considered a case. In particular,the PPV decreased by 24.1% when the stage I PC group
was considered in the comparison group.
Multiple models were run, individually excluding each
covariate, to assess the change of the −2 Log Likelihood
value and the C-statistic. Analyses were terminated when
the model with the lowest −2 Log Likelihood value and
highest C-statistic was determined for each of the two
analysis methods (Tables 7 and 8).
ROC curves (Figures 1, 2, 3 and 4) demonstrate the
validity of analysis method 1 and 2, respectively and
the difference between the existing PC screening test
(PSA alone) and the PBCDR. Confidence intervals be-
tween PSA alone and PBCDR models (PSA + lab bio-
markers) did not overlap and were statistically
significantly different. The ROC AUC: Method 1 PSA
alone 0.59, (95% CI 0.55, 0.61) to PBCDR (PSA+ sig-
nificant lab biomarkers) 0.68 (95% CI 0.65, 0.71);
Method 2 PSA alone 0.63, (95% CI 0.58, 0.66) to
PBCDR (PSA+ significant lab biomarkers) 0.72 (95%
CI 0.68, 0.75).
To determine the ideal cut-points for recommend-
ing prostate biopsy, four different cut-points where
chosen, each providing either increased sensitivity or
specificity. The cut-points are presented in four
ways:
 Cut-point 1 – The maximum likelihood ratio. This
was determined by dividing the sensitivity by 1- the
specificity (SEN/1-SPC), thus maximizing the
quotient.
 Cut point 2 – The probability that yielded a
sensitivity of approximately 90% with the highest
corresponding specificity.
 Cut point 3 – The probability that yielded a
sensitivity of approximately 80% with the highest
corresponding specificity.
 Cut point 4 – The probability that yielded a
specificity of approximately 80% with the highest
corresponding sensitivity (Table 9).
Table 2 Mean value and SD of Lab biomarkers by Prostate biopsy results
Prostatitis BPH PIN PC stage I PC stage II PC stage III PC stage IV
N=342 N=282 N=138 N=332 N=220 N=48 N=16
Albumin
Mean 4 3.98 4.09 4.04 4 3.95 3.9
SD 0.38 0.37 0.37 0.38 0.42 0.39 0.42
HGB *
Mean 14.27 14.24 14.3 14.17 13.7 12.59 12.84
SD 1.54 1.76 1.68 1.66 1.87 2.2 14.08
RBC
Mean 4.67 4.65 4.76 4.69 4.63 4.58 4.5
SD 0.46 0.52 0.52 0.5 0.57 0.44 0.67
Creatinine
Mean 1.25 1.16 1.2 1.16 1.15 1.14 1.13
SD 0.7 0.32 0.35 0.56 0.34 0.39 0.2
PSA*
Mean 8.06 7.99 7.67 9.7 14.12 21.85 44.03
SD 6.74 11.2 4.58 11.66 29.27 30.21 48.71
MCV
Mean 90.78 91.13 90.09 91.17 90.98 90.23 92.24
SD 4.65 5.35 5.79 5.05 6.11 4.18 4.99
Bilirubin
Mean 0.66 0.65 0.6 0.66 0.67 0.65 0.6
SD 0.4 0.3 0.25 0.35 0.35 0.34 0.3
BUN*
Mean 17.98 17.6 17.23 16.53 17.4 16 15.97
SD 6.93 7.9 6.5 6.56 6.73 6.74 4.54
Platlet
Mean 230.45 227.63 240.81 226.54 232.5 234.3 235.44
SD 59.16 61.56 84.31 62.26 69.25 68.07 50.76
WBC
Mean 7.24 7.11 7.42 7.19 7.13 10.41 7.37
SD 2.11 2.17 3.24 2.42 2.08 17.78 1.84
Folate
Mean 12.93 12.56 12.31 13.37 11.92 10.71 10.03
SD 5.44 5.78 5.29 5.25 5.43 5.44 4.99
LDH
Mean 426.91 424.78 371.84 404.6 406.41 392.11 393.33
SD 375.09 144.84 185.54 155.38 158.19 170.98 73.76
*Trend significance (P<0.05).
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the PBCDR. Within each analysis method the PBCDR
has increased PPV percentages, respectively.
To evaluate our hypothesis that there exists a gradi-
ent between specified lab biomarkers and increasing
PC stage, the mean values of each specified laboratorybiomarker (with accompanying 95% CI) was deter-
mined for each PC stage. In agreement with our hy-
pothesis, we observed a change in the mean value of
the biomarkers, HGB, RBC, Albumin and PSA, away
from the normal reference levels as the PC stage
increased (Table 11).
Table 3 Odds ratio and 95% CI for method 1: PC (all
stages) vs. non-cancerous conditions, per laboratory unit
Covariates included Odds ratio OR 95% confidence interval














Table 5 Summary table of independent variables that
demonstrate statistically significant relations with PC (by
analysis methods 1–2)
Independent variable Method 1 Method 2






*P <0.05, ** P <0.001.
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or not the change seen with lab biomarkers HGB, RBC,
Albumin, and PSA was statistically significant. Models
were analyzed by first coding each continuous laboratory
biomarkers as the criterion variable, with the PC stage
coded as the predictor. The model results suggest that
PC stage is a significant statistical predictor for gradient
changes in HGB, RBC count, Albumin, and PSA.
A case example providing a glimpse of the real world
application of the proposed PBCDR is outlined below
(Table 12).
Patient’s PBCDR Total Sum –2.68 <–0.16. Recommen-
dation? No Biopsy for patient.Table 4 Odds ratio and 95% CI for method2: PC (stage II,
III, IV) vs. other (PC stage I, PIN, BPH, prostatitis), per
laboratory unit
Covariates included Odds ratio OR 95% confidence interval














The persistent inability to differentiate between indolent
and aggressive PC has been one of the major limitations
of PSA PC screening. To our knowledge, evaluating
combinations of laboratory biomarkers, used concomi-
tantly with an elevated PSA, has not been researched as
a PSA augmentation strategy. Therefore, the key focus
of this study was to determine if the laboratory biomar-
kers under evaluation were related to more advanced/
aggressive PC stages. Our study found that HGB
(OR=1.42 95% CI 1.27-1.59), RBC count (OR=2.52 95%
CI 1.67-3.78), PSA (OR=1.04 95% CI 1.03-1.05), serum
creatinine (OR=1.55 95% CI 1.12-2.15), and ‘Black” eth-
nicity (OR=1.88 95% CI 1.25-2.85) were significantly
related to the PC group (method 1 PC stages I-IV). RBC
count (p < 0.0001), HGB (p < 0.0001) and creatinine (p
< 0.05) demonstrated increased PC risk with a 1 unit
negative change in their value; while age (p < 0.005),
PSA value (p < 0.005), and MCV level (p < 0.0001)
demonstrated increased PC risk with 1 unit positive in-
crease in their respected values (consistent with what
one would expect). Analysis method 2 (PC stage I in
comparison group) demonstrated HGB (OR 1.47 95% CI
1.31, 1.61), RBC count (OR 2.15 95% CI 1.43, 3.23),
serum creatinine (OR 1.83 95% CI 1.18, 2.85), PSA (OR
1.033 95% CI 1.02, 1.05), MCV (OR 1.05 95% CI 1.02,
1.08), and age (OR 1.018 95% CI 1.01, 1.04) were signifi-
cantly related to PC stages II-IV. ROC curves were com-
pared to address whether the addition of these
significant lab biomarkers would improve PC prediction
when compared to PSA alone. The AUC increased from:
Primary Analysis PSA alone 0.59, (95% CI 0.55, 0.61) to
PBCDR best fit model 0.68, (95% CI 0.65, 0.71); Second-
ary Analysis PSA alone 0.63, (95% CI 0.58, 0.66), toTable 6 Positive predictive value of PSA > 4 ng/dL
Comparison groups Method 1 Method 2
PC Cases/Total biopsies 616/1,378 284/1,378
Positive Predictive Value 44.70% 20.60%
Method 1: PC (all stages) vs. non-cancerous conditions (PIN, BPH, prostatitis).
Method 2: PC (stage II, III, IV) vs. other (stage I PC, PIN, BPH, prostatitis).
Table 7 Best fit logistical regression for method 1: risk of
PC with lab biomarkers and 95% CI, per laboratory unit
method 1: PC (all stages) vs. non-cancerous conditions
(PIN, BPH, prostatitis)
Parameter ML Est. SE OR 95% CI C stat −2 LL
Intercept −7.9494 1.88 xx xx 0.68 1777.339
HGB* −0.3519 0.06 0.70 (0.63-.79)
RBC* −0.9227 0.21 0.40 (0.26-0.60)
Hematuria* −0.2874 0.15 0.75 (0.56-1.01)
Creatinine* −0.4393 0.17 0.65 (0.47-0.89)
Black* 0.6336 0.21 1.89 (1.25-2.90)
PSA* 0.0408 0.08 1.04 (1.03-1.06)
AGE* 0.0196 0.01 1.02 (1.01-1.03)
MCV* 0.0663 0.02 1.07 (1.04-1.10)
Albumin 0.2871 0.16 1.33 (0.98-1.82)
*P < 0.05.
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ences between the models are statistically significant. In
addition to the ROC curve, the validity (sensitivity/specifi-
city) and positive/negative predictive values were deter-
mined. For the PSA only model, one can only determine
the positive predictive value, given patients with a PSA less
than 4 ng/dL are not routinely forwarded for prostate
biopsy. The PPV of PSA alone (> = 4 ng/dL) decreased
from 44.7% (method 1) to 20.6% (method 2). This indi-
cates PSA is less effective as a tool for identifying the more
clinically relevant PC (stages II-IV). Conversely, the PPV
of the PBCDR method 2 (cut point 1) model was 55.3%,
with a NPV of 81.9%, and specificity of 96.2%. These
values demonstrate the PBCDR yielded significantly higher
validity and predictive scores than that of PSA alone. In
alignment with our hypothesis that there exists a gradient
of change between the significant lab biomarkers and
increasing levels of PC; HGB, RBC, PSA and Albumin
demonstrated a significant gradient.Table 8 Best fit logistical regression model for method 2:
risk and 95% CI for PC with lab biomarkers, per
laboratory unit
Parameter ML Est. SE OR 95% CI C Stat −2 LL
Intercept −5.1041 xx xx xx 0.713 1276.366
HGB* −0.3784 0.05 0.69 (0.62, 0.76)
RBC* −0.7641 0.21 0.46 (0.30, 0.70)
Creatinine* −0.6069 0.23 0.55 (0.35, 0.85)
PSA * 0.0325 0.01 1.03 (1.02, 1.05)
Age* 0.0183 0.01 1.02 (1.01, 1.04)
MCV* 0.0488 0.02 1.05 (1.02, 1.08)
Black 0.3612 0.24 1.44 (0.90, 2.31)
*P <0.001.One important potential benefit of the PBCDR model is
a reduction in prostate biopsies. In our study population,
the PPV of PSA alone (in identifying stage II-IV PC) was
20.6% (284/1378). The PBCDR model (Method 2, cut-
point 1), yielded a positive predictive value of 55.3%
(52/94), a specificity of 96.2%, and sensitivity of 18.3%. If
this particular PBCDR model was employed (as opposed
to PSA alone), the number of unnecessary biopsies (those
that did not identify PC stage II-IV) would have been
reduced from 1,092 to 92. Moreover, with a specificity of
96.2%, the PBCDR model would correctly identify greater
than 9 out of every 10 men who do not have PC. In 1998,
the JH VA performed 1,610 biopsies. If one were to apply
the PBCDR (comparing PC stage II-IV vs. stage I PC, PIN,
BPH, and prostatitis) to the 1,378 subjects within this
study, 52 of the 92 total biopsies (PPV= 55.3%) would have
been positive for PC versus the PSA alone (PPV 44.7%). In
addition, if the PBCDR would have been employed,
approximately 1,052 negative biopsies would not have
been performed. This would have resulted in a substantial
decrease in cost for the VA, as well as reduced anxiety for
the patient, and a reduced risk of biopsy morbidity (given
the biopsies would have never been performed).
Our study was consistent with previous published
reports in many ways. The proportion of PC that was
localized to the prostate is consistent with the screening
stage shift phenomenon (increased amounts of pre-
clinical disease are detected), with Stage I comprising
53.9% of all PC cases; Stage II 35.7%; Stage III 7.8%; and
Stage IV 2.59% (data not shown).
Secondly, all laboratory biomarkers demonstrated
‘movement’ in the direction away from the ‘normal’ value
that is consistent with previous literature and is biologi-
cally plausible.15 For instance, the mean PSA value
increased from 7.67 (prostatitis) to 44.03 (stage IV PC).
Multiple published studies have reported that a low
hemoglobin value is an independent risk factor for poor
survival outcomes in patients with hormone refractory PC
[11]. In addition; the correlation between PC and
hematologic disorders has been long recognized for its
clinical significance, with anemia a frequent clinical mani-
festation of advancing PC [9,11]. In this study, the la-
boratory parameters HGB, RBC count, and MCV
(all indicators of hematologic state) demonstrated values
below their normal reference range in patients with
clinically relevant PC (stage II-IV). When comparing the
subjects with histologically confirmed prostatitis to
patients with histologically confirmed stage III PC, the dif-
ference becomes evident. HGB decreased from 14.27 to
12.59 (p < 0.05), RBC count decreased from 4.67 to 4.58
(p < 0.05). Lastly, there was an 83% increase in the risk of
PC for African American (AA) men when compared to
Caucasian men, which is consistent with AA ethnicity as
being a major PC risk factor [8].
Figure 1 Diagnostic statistics = ROC curve of PSA Alone - Method 1.
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may be subjected to a less or more stringent screening
with respect to PC than are other men in the general U.
S. population and therefore may not be representative to
non-VA healthcare system patient populations. In
addition, certain laboratory biomarkers had incomplete
data which lead to the exclusion for analysis and inter-
pretation. Although clinicians often obtain a complete
blood count (CBC), basic metabolic panel (BMP), and
urinalysis (UA) at the time of PSA screening, certain
assays (e.g. PT/aPTT, and Folate) are not routinely
included in these panels. Both PT and aPTT are used toFigure 2 Diagnostic statistics = ROC curve of PSA + lab biomarkers -evaluate the coagulation system, with increasing levels of
both being an independent predictor of disseminated
intravascular coagulation (a systemic condition seen
occasionally with metastatic PC) [12]. A high plasma
levels of Folate has been previously reported as both
protective and as a risk factor for PC development [13].
Given the plausible links to PC, they warrant further
investigation.
Although each prostate biopsy was evaluated by two
or more trained pathologists, the possibility that mis-
classification of disease status (i.e. patients who have PC
were classified as ‘no PC’) does exist. Given that theMethod 1.
Figure 3 Diagnostic statistics = ROC curve of PSA Alone - Method 2.
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http://www.biomedcentral.com/1471-2490/13/6outcome variable (PC yes or no) is determined by the
results of a prostate biopsy, and that the biopsies them-
selves are a sampling of the entire prostate, there is a
chance that the biopsy did not contain cancerous cells,
yet the prostate itself does. However it is unlikely that
an individual would be categorized as having PC if the
carcinoma was not present on histological sample. It is
more likely that a patient with PC is misclassified as not
having PC, which would drive the results towards the
Null hypothesis.
Other variables were not available for analysis. Infor-
mation on PC family history was lacking in patientFigure 4 Diagnostic statistics = ROC curve of PSA + lab biomarkers -notes; and family history on any medical condition was
available in less than 50% of the study participants. In
addition, tobacco, alcohol use, and socio-economic sta-
tus were unavailable for analysis.
A case–control design was utilized in this study. This
type of design was employed as PC cases and suitable
comparison subjects were identified and compared with
respect to their lab values and prior exposures. While
this design provided greater statistical efficiency, the po-
tential for uncontrolled confounding and selection bias
exists. Although the PBCDR tool can be used with all
ages and PSA values, the lack of prostate biopsies inMethod 2.
Table 9 Sensitivity, specificity, PPV, and NPV for
probability cut-off points
Method 1 Method 2
Cut-point 1 (MLE) Probability .45 Probability .41
Sensitivity 52.1 % 18.3 %
Specificity 74.0 % 96.2 %
PPV 61.8 % 55.3 %
NPV 65.7% 81.9 %
Cut-point 2 (Sen. 90%) Probability .33 Probability .13
Sensitivity 90.9 % 89.8 %
Specificity 17.6 % 28.0 %
PPV 47.1 % 20.6 %
NPV 70.5 % 91.3 %
Cut-point 3 (Sen. 80%) Probability .37 Probability .15
Sensitivity 80.5 % 78.2 %
Specificity 37.1 % 45.0 %
PPV 50.9 % 28.7 %
NPV 70.2 % 88.8 %
Cut-point 4 (Spc. 80%) Probability .48 Probability .23
Sensitivity 39.9 % 45.8 %
Specificity 81.4 % 79.5 %
PPV 63.4 % 36.7 %
NPV 62.6 % 85.0 %
Table 11 Mean value, SD, and 95% CI of lab biomarkers
by PC stage
PC Stage A PC Stage B PC Stage C PC Stage D
N=332 N=220 N=48 N=16
Albumin*
Mean 4.04 4.00 3.95 3.90
SD 0.38 0.42 0.39 0.42
95%CI (4.00, 4.08) (3.96, 4.05) (3.84, 4.06) (3.69, 4.11)
HGB*
Mean 14.17 13.70 12.59 12.84
SD 1.66 1.87 2.20 14.08
95%CI (14.00, 14.35) (13.45, 13.95) (11.97, 13.21) (5.94, 19.74)
RBC *
Mean 4.69 4.63 4.58 4.50
SD 0.50 0.57 0.44 0.67
95%CI (4.64, 4.74) (4.55, 4.71) (4.46, 4.70) (4.17, 4.83)
Creatinine
Mean 1.16 1.15 1.14 1.13
SD 0.56 0.34 0.39 0.20
95%CI (1.10, 1.22) (1.11, 1.20) (1.03, 1.25) (1.03, 1.23)
PSA*
Mean 9.70 14.12 21.85 44.03
SD 11.66 29.27 30.21 48.71
95%CI (8.45, 10.95) (10.25, 17.99) (13.31, 30.39) (20.16, 67.90)
MCV
Mean 91.17 90.98 90.23 92.24
SD 5.05 6.11 4.18 4.99
95%CI (90.63, 91.71) (90.17, 91.79) (89.05, 91.41) (89.79, 94.69)
Bilirubin
Mean 0.66 0.67 0.65 0.60
SD 0.35 0.35 0.34 0.30
95%CI (0.28, 1.04) (0.62, 0.72) (0.60, 0.70) (0.45, 0.75)
BUN
Mean 16.53 17.40 16.00 15.97
SD 6.56 6.73 6.74 4.54
95%CI (15.82, 17.24) (16.51, 18.29) (17.91, 14.09) (13.74, 18.20)
Platlet
Mean 226.54 232.50 234.30 235.44
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ing the effectiveness of the PBCDR in this important
group.
Despite these limitations, our study has important
strengths. This study was completed on a robust sample
population (1,378 subjects, of which 616 had PC), and
this high proportion of cases increases overall study
power and statistical efficiency. This increased study
power afforded us the opportunity to stratify on key
parameters, such as PC stage and ethnicity. The results
are biologically plausible and consistent with existing
knowledge. It is accepted that there is a relationship be-
tween PC and systemic diseases that occur in the pres-
ence of both local and metastatic spread of PC [9].
Moreover, it has been demonstrated that the specified
laboratory biomarkers evaluated in this study are highlyTable 10 Comparison of PPV between PSA (> 4ng/dL) and
cut-points 1–4 by analysis method
Method 1 Method 2
Crude PPV 44.7 % 20.6 %
Cut-point 1 61.8 % 55.3 %
Cut-point 2 47.1 % 20.6%
Cut-point 3 50.9 % 28.7%
Cut-point 4 63.4 % 36.7%
SD 62.26 69.25 68.07 50.76
95%CI (219.8, 233.2) (223.4, 241.7) (215.1, 253.6) (210.6, 260.3)
WBC
Mean 7.19 7.13 10.41 7.37
SD 2.42 2.08 1.78 1.84
95%CI (6.93, 7.45) (6.86, 7.40) (9.91, 10.91) (6.47, 8.27)
* P <0.05.
Table 12 Case example utilizing method 2, cut-point 1
Prob. .41/1-.41 = -0.16 Patients value Parameter estimate Pt. value *Parameter estimate Intercept
HGB 15.2 -0.378 -5.74 -5.10
RBC 4.50 -0.764 -3.44
Black (Yes=1) 0 0.361 0.00
Age 60 0.018 1.08
PSA 4.3 0.033 0.129
Creatinine 1.65 -0.601 -0.99
MCV 90.00 0.050 4.5
sum of B*value 2.42
Plus intercept=Sum -2.68
The probability of this cut-point is .41, therefore the Log OR p/1 – p = .41/1-.41, thus the cut-point is −0.16. (If the number yielded from the equation is above
this value, the patient should be referred for prostate biopsy). The patient is a 60 year old, Caucasian male with a recent PSA test value of 4.3 ng/dL. In addition,
he had additional lab work to include a HGB, RBC count, MCV, Creatinine, and a negative test for Hematuria. Utilizing method 2, cut-point 1, the Patient’s PBCDR
total sum is -2.68, which is less than -0.16. Therefore, the recommendation is no biopsy for the patient.
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spread [11].
Men with PC have been described as falling into one
of four groups, and screening can only really benefit
one. The first group consists of men with normally pro-
gressing disease that is identified clinically; the second
group includes men with PC that advances very rapidly.
For the above two groups, screening is of little benefit.
The third group contains men with screen-detected PC
that would have never advanced to clinically relevant
disease; therefore they are exposed to unnecessary pro-
cedures and treatments. Lastly, group four contains
asymptomatic men who have PC identified through
screening and receive beneficial outcomes that otherwise
would have been deprived if not for the screening [8].
One difficulty in PC screening is identifying group 4
relative to group 3. The results of this study suggest that
the PBCDR might improve our ability to detect PC while
also decreasing the number of prostate biopsies. More-
over, the PBCDR seems to be more accurate with PC
stages II-IV, providing a novel, simple to implement,
inexpensive tool that has the potential to separate more
severe PC from indolent PC. This has important impli-
cations, especially if PSA is used as a cost effective PC
screening program. The overlap of PSA values in men
with PC and non-cancerous prostate conditions has
been well documented. A thorough physical exam with
DRE is the mainstay of PC detection, and a patient’s life
expectancy and co-morbidities should be considered
when developing a unique treatment course of action.
However this study provides a glimpse of the potential
benefit that these additional lab parameters can provide.
In conclusion, our study results suggest that evaluating
certain biomarkers in conjunction with PSA may improve
PC prediction prior to biopsy. Moreover, the biomarkers
may be more helpful in detecting clinically relevant PC.
Follow-up studies should begin with replicating this studyon different U.S. VA patient populations, involving multiple
practices, capturing PC family history, and evaluating other
biomarkers (such as PSA values lower than 4.0 ng/dl,
PT/aPTT and folate) that may assist in improving PC
screening efficiency.
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